Skip to main content

Table 3 Acute toxicity profile

From: The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity

CCRT toxicity Arm A (cisplatin 100 mg/m2) Arm B (cisplatin 40 mg/m2) p
N = 26 N = 24
Overall toxicity
 Grade 2 5 (19.2%) 2 (8.3%) 0.020*
 Grade 3 21 (80.8%) 16 (66.7%)
 Grade 4 0 (0%) 6 (25.0%)
Non-hematologic
Mucositis
 < Grade 3 16 (61.5%) 6 (25.0%) 0.012*
 ≥ Grade 3 10 (38.5%) 18 (75.0%)
Pharyngitis
 < Grade 3 12 (46.2%) 11 (45.8%) 1.000
 ≥ Grade 3 14 (53.8%) 13 (54.2%)
Stomatitis
 < Grade 3 12 (46.2%) 11 (45.8%) 1.000
 ≥ Grade 3 14 (53.8%) 13 (54.2%)
Laryngeal edema
 < Grade 3 23 (88.5%) 23 (95.8%) 0.611
 ≥ Grade 3 3 (11.5%) 1 (4.2%)
Dermatitis
 < Grade 3 24 (92.3%) 22 (91.7%) 1.000
 ≥ Grade 3 2 (7.7%) 2 (8.3%)
Nausea/vomiting
 < Grade 3 23 (88.5%) 19 (79.2%) 0.456
 ≥ Grade 3 3 (11.5%) 5 (20.8%)
Hematologic
Anemia
 < Grade 3 25 (96.2%) 23 (95.8%) 1.000
 ≥ Grade 3 1 (3.8%) 1 (4.2%)
Leukopenia
 < Grade 3 26 (100%) 21 (87.5%) 0.103
 ≥ Grade 3 0 (0%) 3 (12.5%)
Neutropenia
 < Grade 3 26 (100%) 23 (95.8%) 0.480
 ≥ Grade 3 0 (0%) 1 (4.2%)
Thrombocytopenia
 < Grade 3 26 (100%) 24 (100%) NS
 ≥ Grade 3 0 (0%) 0 (0%)
  1. Abbreviations: CCRT = concurrent chemoradiotherapy; NS = no statistics were computed.
  2. * Statistically significant, p < 0.05.